Literature DB >> 9593130

Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime).

W L Roberts1, W J McMurray, P M Rainey.   

Abstract

Meglumine antimonate (Glucantime), a drug of choice for the treatment of leishmaniasis, is produced by the reaction of pentavalent antimony with N-methyl-D-glucamine, a carbohydrate derivative. We investigated the structure and composition of meglumine antimonate, which remain poorly understood, despite 50 years of use. Measurement of the antimony content of meglumine antimonate powder indicated a 1:1.37 molar ratio of antimony to N-methyl-D-glucamine. Osmolality measurements performed with meglumine antimonate solutions demonstrated an average of 1.43 antimony atoms per molecule of meglumine antimonate. The osmolality of a 1:10 dilution of stock meglumine antimonate increased by 45% over 8 days, suggesting hydrolysis to less complex species. A comparison of the proton nuclear magnetic resonance spectra of N-methyl-D-glucamine and meglumine antimonate revealed an increase in complexity in the latter but with all of the resonances of the former still being evident, consistent with the presence of coordination complexes between antimony and each of the N-methyl-D-glucamine hydroxyls. Fast atom bombardment and electrospray ionization mass spectrometry coupled with several derivatization procedures provided evidence that up to four N-methyl-D-glucamine hydroxyls are coordinated with each antimony. A series of oligomers were observed. The major moiety has a molecular mass of 507 atomic mass units and consists of NMG-Sb-NMG, where Sb represents antimony and NMG represents N-methyl-D-glucamine. Additional species containing up to four antimony atoms and five N-methyl-D-glucamine moieties and corresponding to the general form (NMG-Sb)n-NMG are also present. These results suggest that this agent is a complex mixture that exists in equilibrium in aqueous solution.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593130      PMCID: PMC105748          DOI: 10.1128/AAC.42.5.1076

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Control of the leishmaniases. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

2.  Linkage positions in glycoconjugates by periodate oxidation and fast atom bombardment mass spectrometry.

Authors:  A S Angel; B Nilsson
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

3.  The leishmaniases.

Authors:  E A Steck
Journal:  Prog Drug Res       Date:  1974

4.  Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam).

Authors:  J D Berman; M Grogl
Journal:  Exp Parasitol       Date:  1988-10       Impact factor: 2.011

5.  Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy.

Authors:  W L Roberts; P M Rainey
Journal:  Anal Biochem       Date:  1993-05-15       Impact factor: 3.365

6.  Antileishmanial activity of sodium stibogluconate fractions.

Authors:  W L Roberts; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

  6 in total
  9 in total

Review 1.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

2.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

3.  Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.

Authors:  Samanta Etel Treiger Borborema; João Alberto Osso; Heitor Franco de Andrade; Nanci do Nascimento
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-08       Impact factor: 2.743

4.  Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.

Authors:  Antonia Mr Franco; Iryna Grafova; Fabiane V Soares; Gennaro Gentile; Claudia Dc Wyrepkowski; Marcos A Bolson; Ézio Sargentini; Cosimo Carfagna; Markku Leskelä; Andriy Grafov
Journal:  Int J Nanomedicine       Date:  2016-12-13

Review 5.  Leishmaniasis: a review.

Authors:  Edoardo Torres-Guerrero; Marco Romano Quintanilla-Cedillo; Julieta Ruiz-Esmenjaud; Roberto Arenas
Journal:  F1000Res       Date:  2017-05-26

Review 6.  Pentavalent antimonials: new perspectives for old drugs.

Authors:  Frédéric Frézard; Cynthia Demicheli; Raul R Ribeiro
Journal:  Molecules       Date:  2009-06-30       Impact factor: 4.411

7.  In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmania infantum.

Authors:  Saied Soflaei; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Mojtaba Shakibaie; Ahmad Reza Shahverdi; Mohsen Shafiepour
Journal:  J Parasitol Res       Date:  2012-06-26

8.  Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.

Authors:  Deise Riba Coelho; Elaine Silva Miranda; Tatiana Dillenburg Saint'Pierre; Francisco José Roma Paumgartten
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-07       Impact factor: 2.743

9.  First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report.

Authors:  Omid Mozafari; Seyed Afshin Shorofi; Seyde Sedighe Yousefi
Journal:  Iran J Public Health       Date:  2016-09       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.